TaiGen Biotechnology Completes Recruitment for Phase II Trial of Nemonoxacin

TaiGen Biotechnology announced the successful completion of patient recruitment for the global double-blind Phase II clinical trial of Nemonoxacin for the treatment of adult community-acquired pneumonia.

A total of 265 patients have been admitted to the trial, and TaiGeb said it expects completion of data analysis in the last quarter.

According to the company, the trial will look at the effect of Nemonoxacin (TG-873870) in comparison with levofloxacin, the leading quinolone on the market.